SS-31 Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is SS-31?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Mitochondrial disease, heart failure, ischemia-reperfusion injury, renal protection, neurodegeneration, skeletal muscle disorders
• First Discovered: Late 1990s, Weill Cornell Medical College, during opioid receptor pharmacology research
• Molecular Weight: 639.8 g/mol
• Research Status: Over 50 clinical trials completed or underway; hundreds of preclinical investigations published
• Key Mechanisms: Cardiolipin binding and membrane stabilization, respiratory supercomplex assembly, direct ROS scavenging, ATP synthasome stabilization
• Published Studies: Among the most clinically advanced mitochondria-targeted peptides in the research literature
• Clinical Trial Status: Phase 2 and Phase 3 human trials completed across multiple disease areas; FDA accelerated approval granted September 2025 for Barth syndrome
• Regulatory Classification: FDA-approved (Forzinity) for Barth syndrome; research use only for all other applications; WADA status under review as of 2025

What is SS-31?

SS-31 is a synthetic tetrapeptide belonging to the Szeto-Schiller class of aromatic-cationic peptides, named for the researchers who discovered them: Dr. Hazel Szeto and Peter Schiller. Its clinical development name is elamipretide, and it received FDA accelerated approval in September 2025 under the brand name Forzinity for the treatment of Barth syndrome, a rare inherited mitochondrial disorder. In the research literature, it also appears as Bendavia and MTP-131.

The peptide’s origin is unusual. Scientists at Weill Cornell Medical College were studying opioid receptor pharmacology in the late 1990s when they noticed that certain tetrapeptides improved mitochondrial function through a mechanism entirely separate from opioid receptor activity. That serendipitous observation launched more than two decades of dedicated research into what would become one of the most extensively studied mitochondria-targeted compounds in biomedical science.

What makes SS-31 distinctive among research peptides is where it goes and what it does when it gets there. Unlike most peptides that act at cell surface receptors, SS-31 penetrates cell membranes and concentrates at the inner mitochondrial membrane, reaching concentrations approximately 5,000 times higher than the surrounding cellular environment. It does this without relying on mitochondrial membrane potential for uptake, a significant practical advantage over other mitochondria-targeting compounds. Once localized, it binds to cardiolipin, a phospholipid found exclusively in the inner mitochondrial membrane that is essential for energy production.

Mitochondria power nearly every energy-demanding biological process, from cardiac contraction to neural signaling to muscle movement. When mitochondrial function deteriorates, whether through inherited disease, aging, ischemia, or oxidative stress, the consequences appear across essentially every organ system. SS-31 research addresses this fundamental problem by targeting the bioenergetic machinery directly rather than through upstream signaling pathways.

The compound has now been studied in animal models, cell cultures, and human clinical trials spanning heart failure, kidney disease, mitochondrial myopathy, Barth syndrome, neurodegeneration, and aging-related decline. Its 2025 FDA approval marks the first approval of any mitochondria-targeted therapeutic and establishes a proof-of-concept for the entire class of cardiolipin-binding peptides.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

SS-31 consists of four amino acids arranged in a specific sequence that creates an alternating pattern of aromatic and cationic residues. This alternating architecture gives the molecule an amphipathic character: one face is hydrophobic and aromatic, the other is positively charged. That combination allows SS-31 to penetrate lipid bilayers while maintaining affinity for negatively charged phospholipids like cardiolipin.

The D-arginine residue at position one confers resistance to peptidase enzymes. Most peptides are rapidly cleaved by proteases in plasma and tissue, but the D-form of arginine is not recognized by standard peptidases, extending SS-31’s functional half-life in biological environments.

Dimethyltyrosine (Dmt) at position two is a non-standard amino acid with two methyl groups added to the tyrosine ring. This modification provides intrinsic antioxidant capacity by enabling direct reactive oxygen species (ROS) scavenging. Dmt was also the residue responsible for the unexpected opioid receptor activity observed during SS-31’s original discovery, though opioid activity is considered irrelevant to its mitochondrial mechanism.

The C-terminal phenylalanine is presented as an amide (Phe-NH₂) rather than a free carboxylate. This amidation increases lipophilicity at the C-terminus, improving membrane association. Together, these four residues create a compact molecule that inserts into the inner mitochondrial membrane with high selectivity and achieves the extraordinary concentration gradient that defines SS-31’s pharmacology.

Mechanisms of Action Being Investigated

SS-31 operates through multiple interconnected mechanisms, all centered on the inner mitochondrial membrane. The primary anchor point is cardiolipin, but the downstream effects extend across electron transport, ATP synthesis, ROS biology, apoptotic signaling, and mitochondrial network dynamics.

Cardiolipin Binding and Membrane Stabilization

Cardiolipin is an anionic phospholipid found exclusively in the inner mitochondrial membrane. It contains four acyl chains and two phosphate groups, giving it a distinctive structure that supports the curvature of cristae and anchors the protein complexes responsible for electron transport and ATP synthesis. Cardiolipin deficiency or oxidative damage to cardiolipin directly impairs mitochondrial function across multiple disease states.

SS-31 binds cardiolipin through electrostatic interactions between its cationic residues (D-arginine and lysine) and cardiolipin’s negative phosphate groups, combined with hydrogen bonding and hydrophobic insertion of the aromatic residues into the lipid bilayer. Chemical cross-linking studies combined with mass spectrometry confirmed that SS-31 localizes specifically to cardiolipin-enriched membrane domains where respiratory chain complexes assemble [1].

This binding stabilizes cristae structure, prevents pathological cristae remodeling under stress conditions, and maintains the geometry needed for respiratory supercomplex assembly. It also protects cardiolipin from peroxidation, interrupting the lipid peroxidation cascade that normally propagates oxidative damage through the inner membrane [2].

Respiratory Supercomplex Stabilization and Bioenergetic Optimization

Proteomic analyses published in 2020 identified 12 key protein interactors for SS-31 within the mitochondria, including components of ATP synthase (Complex V), the adenine nucleotide translocator (ANT), electron transport chain complexes III and IV, and creatine kinase [1]. These interactions stabilize what researchers call the ATP synthasome, a supercomplex composed of ATP synthase, ANT, and creatine kinase that functions as the primary unit of ATP production and export.

By stabilizing this supercomplex, SS-31 improves the efficiency of ADP-to-ATP conversion and enhances ADP uptake by ANT. Studies in aged skeletal muscle mitochondria confirmed that SS-31 increases ADP uptake capacity, directly improving the energetic response to physiological demand [3]. The net effect is improved oxidative phosphorylation efficiency in energy-depleted mitochondria, achieved through structural stabilization rather than transcriptional upregulation.

ROS Scavenging and Antioxidant Activity

SS-31 provides both direct and indirect antioxidant protection. The Dmt residue directly neutralizes hydrogen peroxide, hydroxyl radicals, and peroxynitrite in a dose-dependent manner. This ROS scavenging occurs at the inner mitochondrial membrane, the primary site of oxidant generation within the electron transport chain, a mechanistic advantage over systemic antioxidants that do not concentrate at this location [4].

Beyond direct scavenging, SS-31 upregulates endogenous antioxidant enzymes including superoxide dismutase isoforms SOD1 and SOD2, and catalase. It reduces mitochondrial ROS production by improving electron flux efficiency through the respiratory chain, decreasing electron leak to molecular oxygen. Protection extends to mitochondrial DNA, which is particularly vulnerable to oxidative damage given its proximity to the electron transport chain and limited repair capacity.

Redox Homeostasis and Post-Translational Modification Reversal

Aging and oxidative stress cause accumulation of S-glutathionylation on mitochondrial proteins, a post-translational modification in which glutathione covalently attaches to cysteine residues under oxidative conditions. This modification impairs protein function and contributes to the bioenergetic decline associated with aging and chronic disease. SS-31 reverses pathological S-glutathionylation on multiple mitochondrial proteins, restoring their function [5]. This mechanism distinguishes SS-31 from antioxidants that only prevent new oxidative damage without addressing existing modifications.

Mitochondrial Dynamics and Quality Control

SS-31 promotes formation of larger, more interconnected mitochondrial networks in stressed cells. Fragmented mitochondrial networks are a common feature of disease states and aging, associated with impaired bioenergetics and increased apoptotic susceptibility. SS-31 reduces excessive mitochondrial fission, particularly in diabetic nephropathy models, and inhibits the pathological fragmentation that accompanies ischemic injury [6].

The peptide also enhances mitophagy, the selective autophagy pathway that removes damaged mitochondria from the cell. In hind limb ischemia models, SS-31 restored autophagic flux through AKT-mTOR inhibition, improving mitochondrial quality control and cellular recovery [7]. Together, these dynamics effects support a healthier mitochondrial population rather than simply improving the function of existing, damaged organelles.

Anti-Apoptotic Signaling

SS-31 interrupts multiple steps in the mitochondria-initiated apoptotic pathway. It inhibits cytochrome c release from the inner membrane, reduces BAX protein recruitment to the mitochondrial outer membrane, and prevents opening of the mitochondrial permeability transition pore (mPTP) [8]. mPTP opening is a key event in cell death following ischemia-reperfusion injury, traumatic brain injury, and neurodegenerative processes, making this mechanism particularly relevant across multiple research applications.

Downstream anti-apoptotic effects include increased expression of Bcl-2, decreased levels of cleaved caspase-3, restored SIRT1 expression, and promotion of PGC-1alpha nuclear translocation, which activates transcriptional programs supporting mitochondrial biogenesis. This constellation of effects suggests SS-31 not only prevents acute cell death but may support longer-term mitochondrial renewal.

Anti-Inflammatory Effects

SS-31 inhibits LPS-induced upregulation of IL-6, IL-1beta, and TNF-alpha in inflammatory models. A 2024 review published in Mitochondrion emphasized SS-31’s superiority over natural antioxidants in suppressing inflammation, maintaining mitochondrial dynamics, and preventing apoptosis [9]. Structural derivatives designated 5f and 5g show even greater anti-inflammatory potency than the parent compound, suggesting that targeted chemical modifications may amplify specific aspects of SS-31’s mechanism.

Major Areas of Research

SS-31 research spans an unusually broad range of disease areas, all connected by mitochondrial dysfunction as a shared pathological feature. Each area below summarizes key findings and current research directions.

Mitochondrial Disease and Barth Syndrome

Barth syndrome is a rare X-linked disorder caused by mutations in the TAZ gene, which encodes tafazzin, the enzyme responsible for cardiolipin remodeling. Without functional tafazzin, cardiolipin composition becomes abnormal, impairing mitochondrial function specifically in tissues with high energy demands: the heart, skeletal muscle, and immune system. Patients experience cardiomyopathy, skeletal muscle weakness, exercise intolerance, and neutropenia.

SS-31 directly addresses the underlying defect. By binding the abnormal cardiolipin present in Barth syndrome mitochondria, SS-31 partially compensates for the structural and functional deficits caused by defective cardiolipin remodeling. The TAZPOWER Phase 2/3 clinical trial demonstrated 45% improvement in knee extensor muscle strength and 40% enhancement in cardiac stroke volume over 48 weeks, with sustained benefits observed in open-label extension data spanning over eight years [10]. FDA accelerated approval followed in September 2025.

Key Research Highlights:

• 45% improvement in muscle strength in the TAZPOWER randomized trial
• 40% increase in cardiac stroke volume over 48 weeks
• Preclinical evidence that SS-31 restores mitochondrial protein complex assembly in patient-derived cells
• Over eight years of open-label extension safety and efficacy data available

Cardiovascular Research

Heart failure is characterized by progressive mitochondrial dysfunction in cardiomyocytes, with impaired electron transport, reduced ATP production, and increased oxidative stress. SS-31 research in this area spans animal models, explanted human heart tissue, and clinical trials.

In a dog model of advanced heart failure, chronic SS-31 treatment improved both left ventricular function and mitochondrial function, with sustained benefits over the treatment period [11]. More directly relevant to human biology, SS-31 improved mitochondrial respiration in explanted failing human heart tissue, establishing that the mechanism active in animal models is preserved in human cardiac tissue [12].

The PROGRESS-HF Phase 2 clinical trial in human heart failure patients was completed in 2020. While improvements in some functional parameters were observed, the trial did not achieve its primary endpoint of reducing left ventricular end-systolic volume at 24 weeks, highlighting the gap between preclinical promise and clinical translation in this indication [13].

Ischemia-reperfusion injury research, where SS-31 is administered before or during reperfusion following coronary occlusion, shows consistent reduction in infarct size and preservation of cardiac function across multiple animal models.

Key Research Highlights:

• Improved mitochondrial and ventricular function in dog heart failure model
• Preserved mitochondrial function in explanted human failing heart tissue
• Consistent infarct size reduction in ischemia-reperfusion animal models
• PROGRESS-HF trial did not meet primary endpoint in human heart failure patients

Renal Protection and Kidney Disease

The kidneys are among the most metabolically active organs in the body, with renal tubular cells entirely dependent on oxidative phosphorylation for energy. Acute kidney injury (AKI) and chronic kidney disease both involve substantial mitochondrial dysfunction.

A Phase 2a clinical trial in patients with renal artery stenosis demonstrated that SS-31 infusion improved cortical perfusion and reduced oxidative stress markers compared to placebo [14]. This represented one of the first demonstrations of SS-31 activity in a human organ system outside of rare disease. Preclinical data show protection against cisplatin-induced nephrotoxicity, contrast-induced nephropathy, and ischemia-reperfusion kidney injury across multiple animal models.

In diabetic nephropathy models, SS-31 inhibits mitochondrial fission and reduces tubular cell apoptosis, addressing mechanisms that contribute to progressive renal fibrosis. The renal research area has produced some of the most mechanistically detailed preclinical data supporting SS-31’s cardiolipin-binding mechanism [2].

Key Research Highlights:

• Improved renal cortical perfusion and reduced oxidative stress in Phase 2a renal artery stenosis trial
• Protection against multiple forms of experimental acute kidney injury in animal models
• Inhibition of mitochondrial fission and reduced apoptosis in diabetic nephropathy models

Skeletal Muscle and Exercise Research

Skeletal muscle ATP demand during exercise requires rapid and sustained mitochondrial output. Age-related mitochondrial dysfunction in muscle contributes to sarcopenia and exercise intolerance, while primary mitochondrial myopathies represent a disease-specific application.

Phase 2 clinical trials in primary mitochondrial myopathy patients showed dose-dependent increases in muscle ATP production and improved mitochondrial respiratory chain function in some subgroups, though primary endpoints were not consistently met across all mitochondrial myopathy subtypes [15,16]. Variable responsiveness appears related to differences in underlying genetic mutations.

Mechanistic work in aged mouse skeletal muscle showed that SS-31 improves ADP uptake by the adenine nucleotide translocator, directly enhancing the energetic response to contractile activity [3]. Eight weeks of SS-31 treatment in aged mice reversed cardiac aging markers including reduced proton leak, increased membrane potential, and reduced fibrosis, without altering oxidative phosphorylation complex levels, suggesting functional restoration rather than structural upregulation [17].

Key Research Highlights:

• Dose-dependent increases in muscle ATP production in mitochondrial myopathy trials
• Improved ADP uptake in aged skeletal muscle mitochondria
• Reversal of cardiac aging markers in aged mouse model at 8 weeks
• Inconsistent primary endpoint achievement across mitochondrial myopathy subtypes

Neurological and Neuroprotective Research

The brain’s extraordinarily high energy demand makes neurons acutely vulnerable to mitochondrial dysfunction. SS-31 research in neurological applications spans traumatic brain injury, stroke, neurodegeneration, and peripheral neuropathy.

SS-31 prevents mPTP opening following traumatic brain injury and stroke, reducing secondary cell death that occurs during the hours and days following the initial insult. In experimental stroke models, reduced infarct volume and improved functional recovery have been documented. Neurodegenerative disease models, including Alzheimer’s and Parkinson’s research, show SS-31 attenuating mitochondrial fragmentation and reducing amyloid-beta-induced oxidative stress in neuronal cells [8].

Diabetic peripheral neuropathy represents an area of particular interest, as mitochondrial dysfunction in peripheral neurons contributes to sensory deficits. Animal models show SS-31 reducing oxidative stress and improving nerve conduction velocity in diabetic neuropathy paradigms.

Key Research Highlights:

• Reduced infarct volume and improved functional recovery in experimental stroke models
• Prevention of mPTP opening following traumatic brain injury
• Attenuation of mitochondrial fragmentation in Alzheimer’s and Parkinson’s disease models
• Improved nerve conduction velocity in diabetic neuropathy animal models

Aging and Age-Related Decline

The mitochondrial theory of aging posits that cumulative oxidative damage to mitochondria, combined with declining bioenergetic efficiency, drives many features of biological aging. SS-31 research directly tests this framework by examining whether mitochondrial restoration can reverse aging phenotypes.

Studies in aged mice show improvements in cardiac function, skeletal muscle performance, and kidney histology following SS-31 treatment. The reversal of S-glutathionylation on aged mitochondrial proteins provides a specific molecular target linking SS-31’s mechanism to age-related bioenergetic decline [5]. Research interest in longevity applications continues to grow, though no human aging trials have been completed.

Key Research Highlights:

• Reversal of cardiac aging markers in aged mouse models
• Restoration of mitochondrial protein function through S-glutathionylation reversal
• Improved skeletal muscle and renal parameters in aged animal models
• No completed human aging trials available

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

SS-31 is administered by intravenous infusion or subcutaneous injection in clinical and preclinical research. No oral bioavailability data support oral administration. The peptide’s water solubility facilitates preparation of aqueous solutions at concentrations suitable for both delivery routes. In clinical trials, subcutaneous administration demonstrated adequate systemic exposure and was generally well tolerated, with injection site reactions being the most common adverse effect.

Distribution and Metabolism

Following systemic administration, SS-31 distributes rapidly to tissues with high mitochondrial density, including heart, kidney, skeletal muscle, and brain. The peptide achieves approximately 5,000-fold higher concentrations at the inner mitochondrial membrane compared to the surrounding cytoplasm, driven by electrostatic attraction to cardiolipin’s negative charge rather than by mitochondrial membrane potential.

This concentration mechanism operates independently of membrane potential, meaning SS-31 accumulates in dysfunctional mitochondria that have lost membrane potential, a clinically important property because diseased mitochondria often exhibit reduced potential. The peptide does not enter the mitochondrial matrix but remains at the inner membrane surface, consistent with its cardiolipin-binding mechanism.

Delivery Methods Under Investigation

• Intravenous infusion: Used in PROGRESS-HF heart failure trial and renal artery stenosis Phase 2a trial; provides controlled systemic exposure
• Subcutaneous injection: Used in TAZPOWER Barth syndrome trial and primary mitochondrial myopathy trials; practical for outpatient and home administration research
• Local/targeted delivery: Under preclinical investigation for organ-specific applications

Excretion and Clearance

Plasma half-life in humans is approximately 2-4 hours. Standard peptide degradation pathways handle metabolic clearance. However, SS-31 exhibits a notable dissociation between plasma clearance and biological effect duration. Functional improvements in mitochondrial performance and clinical outcomes persist for days to weeks following treatment cessation in multiple study designs.

This prolonged pharmacodynamic effect remains incompletely explained. Proposed mechanisms include tissue retention beyond plasma clearance, activation of downstream signaling cascades that persist after drug removal, structural membrane remodeling effects that outlast drug presence, and possible transcriptional or epigenetic changes induced by the period of bioenergetic improvement. Resolving this mechanistic question has implications for dosing frequency in future clinical applications.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data Quality While SS-31 has been studied in more human trials than most research peptides, the data picture is mixed. The PROGRESS-HF trial in heart failure did not meet its primary endpoint, and primary mitochondrial myopathy trials showed variable efficacy across patient subgroups. The FDA approval for Barth syndrome used accelerated approval on a surrogate endpoint (muscle strength), with confirmatory trials required to demonstrate actual clinical benefit. The full scope of human indications supported by robust Phase 3 data therefore remains narrow.

Mechanistic Understanding The basis of SS-31’s functional selectivity for dysfunctional mitochondria is not fully established. The prolonged biological effect relative to plasma half-life is unexplained. The relative contribution of each mechanism (cardiolipin binding, ROS scavenging, protein interaction, dynamics modulation) to clinical outcomes in specific disease states has not been dissected. Whether the 12 protein interactors identified in proteomic studies are all functionally relevant or represent some binding specificity at scale remains unclear.

Population and Subgroup Specificity Responsiveness to SS-31 appears to vary substantially based on the nature of the underlying mitochondrial defect. Primary mitochondrial myopathy trials demonstrated this variability directly. Predicting which patient populations will respond to SS-31 requires biomarkers that do not yet exist in validated form.

Long-Term Safety Clinical trial data cover treatment durations up to 48 weeks in the TAZPOWER trial, with longer open-label extension data available for Barth syndrome specifically. Systematic long-term safety data for other indications are absent. Chronic effects of sustained mitochondrial membrane interaction are not fully characterized.

Areas Needing Further Investigation

• Validated biomarkers to predict SS-31 responsiveness across disease states
• Mechanism of prolonged pharmacodynamic effect relative to short plasma half-life
• Controlled human trials in aging, neurodegeneration, and renal protection
• Confirmatory Phase 3 data for Barth syndrome to confirm clinical benefit beyond surrogate endpoint
• Systematic drug interaction profiling in human subjects

Regulatory and Research Status

Current Classification

FDA Status SS-31 received FDA accelerated approval on September 19, 2025, for the treatment of Barth syndrome in patients weighing at least 30 kg. The approved product is marketed as Forzinity by Stealth BioTherapeutics. This approval makes SS-31 the first FDA-approved treatment for Barth syndrome and the first FDA-approved mitochondria-targeted therapeutic of any kind.

Accelerated approval was granted on the basis of muscle strength as a surrogate endpoint reasonably likely to predict clinical benefit. Continued approval is contingent on the sponsor completing confirmatory trials demonstrating actual clinical benefit. The compound received Orphan Drug, Fast Track, Priority Review, and Rare Pediatric Disease designations during its development.

For all applications outside of Barth syndrome in eligible patients, SS-31 remains classified as a research compound not approved for human therapeutic use. Researchers at academic and commercial institutions use it under standard research-use-only protocols with appropriate institutional oversight.

WADA Status SS-31 and its analogues fall under categories subject to WADA review given their mitochondrial bioenergetic enhancement potential. Athletes subject to anti-doping testing should verify current WADA prohibited list status before any exposure.

International Perspective The European Medicines Agency has not issued an equivalent approval as of the time of writing. Regulatory status in other major markets follows typical research-chemical classification for non-approved indications. The FDA approval for Barth syndrome will likely accelerate regulatory review internationally given the rare disease designation and the limited treatment alternatives for this patient population.

Research Community Approach

SS-31 research continues at academic centers globally, supported by basic science grants and rare disease research foundations. Stealth BioTherapeutics, the company founded by Dr. Hazel Szeto to commercialize the Szeto-Schiller peptide class, leads clinical development. All research use requires institutional review board oversight for human studies and standard biosafety and ethical compliance for animal work.

Future Research Directions

The most important near-term research priority is completing the confirmatory trials required for Barth syndrome approval. Beyond that, the cardiovascular indication represents the largest potential patient population, but the mixed PROGRESS-HF results necessitate better patient stratification strategies. Biomarker-driven trial designs that select patients based on mitochondrial dysfunction severity or cardiolipin status are the most likely path to demonstrating efficacy in broader indications. Neurological and aging applications remain primarily preclinical and require dedicated human safety and pharmacokinetic studies before efficacy trials are feasible.

Key Research Findings

TAZPOWER Phase 2/3 Barth Syndrome Trial

Research Focus: Efficacy and safety of subcutaneous elamipretide in Barth syndrome patients Key Results: 45% improvement in knee extensor muscle strength at 48 weeks; 40% enhancement in cardiac stroke volume; significant improvement in 6-minute walk test; sustained benefits in open-label extension data spanning over eight years Significance: Provided the clinical evidence base for the first FDA-approved treatment for Barth syndrome and the first approval of any mitochondria-targeted therapeutic Limitations: Accelerated approval on surrogate endpoint; confirmatory trials required; patient population limited to those weighing 30 kg or more [10]

Cardiolipin Binding Mechanism Confirmation

Research Focus: Identifying the precise binding site and protein interactors of SS-31 within mitochondria Key Results: Chemical cross-linking with mass spectrometry confirmed cardiolipin-enriched membrane domain localization; proteomic analysis identified 12 key protein interactors including ATP synthase, ANT, and electron transport chain complexes; surface electrostatic modulation of lipid bilayers confirmed Significance: Provided molecular-level mechanistic foundation for decades of functional observations; identified the ATP synthasome as the structural target of SS-31’s bioenergetic effects Limitations: Primarily in vitro and cell culture data; translation of specific protein interactions to in vivo therapeutic effects requires further characterization [1]

Failing Human Heart Mitochondrial Recovery

Research Focus: Whether SS-31 can improve mitochondrial function in explanted tissue from patients with advanced heart failure Key Results: Elamipretide improved mitochondrial respiratory function in explanted failing human heart tissue; effects were consistent with animal model data Significance: Bridged the gap between animal model findings and human cardiac biology; demonstrated that the cardiolipin-binding mechanism is active in human disease tissue Limitations: Ex vivo tissue preparation; does not confirm in vivo efficacy in living patients with heart failure [12]

PROGRESS-HF Phase 2 Heart Failure Trial

Research Focus: Whether SS-31 would reduce left ventricular end-systolic volume in human heart failure patients Key Results: Treatment was generally well tolerated; some functional parameter improvements observed; primary endpoint of reduced left ventricular end-systolic volume at 24 weeks was not achieved Significance: Illustrates the translational gap between strong animal model data and human clinical outcomes; highlights need for better patient selection and biomarker strategies in heart failure Limitations: Single primary endpoint design; may not have selected the most responsive patient subgroup; 24-week duration may be insufficient for structural cardiac remodeling [13]

Aged Skeletal Muscle Bioenergetics Study

Research Focus: Mechanism of SS-31 action in aged skeletal muscle mitochondria and its effect on exercise energetics Key Results: SS-31 increased ADP uptake by the adenine nucleotide translocator in aged muscle mitochondria; improved energetic response to simulated contractile activity; effect attributed to ANT stabilization within the ATP synthasome Significance: Identified a specific mechanistic basis for SS-31’s exercise-related benefits in aged muscle; connected proteomic interaction data to a functionally measurable outcome Limitations: Animal model; exercise translation to aged humans requires dedicated clinical investigation [3]

Renal Artery Stenosis Phase 2a Trial

Research Focus: Whether SS-31 could improve renal outcomes in patients with atherosclerotic renal artery stenosis Key Results: SS-31 infusion improved renal cortical perfusion and reduced oxidative stress biomarkers compared to placebo in a randomized design Significance: One of the first demonstrations of SS-31 biological activity in a human organ system outside rare disease; established renal protection as a viable clinical research direction Limitations: Small sample size Phase 2a design; surrogate endpoint outcomes; no follow-up Phase 3 trial has been completed [14]

Frequently Asked Questions

What is SS-31 and why do scientists study it?

SS-31 is a synthetic four-amino acid peptide that concentrates at the inner mitochondrial membrane and binds to cardiolipin, a phospholipid essential for energy production. Scientists study it because mitochondrial dysfunction is a common feature of dozens of diseases, from rare inherited conditions to heart failure to neurodegeneration, and SS-31 is one of the few compounds that directly targets the mitochondrial machinery rather than acting through surface receptors or upstream signaling.

What disease received FDA approval involving SS-31?

SS-31, under the brand name Forzinity, received FDA accelerated approval in September 2025 for the treatment of Barth syndrome, a rare genetic disorder caused by mutations affecting cardiolipin remodeling. This approval made SS-31 the first FDA-approved treatment for Barth syndrome and the first FDA-approved mitochondria-targeted therapeutic. The approval applies specifically to patients weighing at least 30 kg.

How does SS-31 differ from other antioxidant compounds studied for mitochondrial health?

Most antioxidants distribute throughout the body without concentrating specifically at mitochondria. SS-31 reaches concentrations roughly 5,000 times higher at the inner mitochondrial membrane than in the surrounding cell, placing its antioxidant activity precisely where mitochondrial oxidants are generated. It also stabilizes the protein complexes responsible for ATP production, an effect that goes beyond simple antioxidant protection and addresses the structural basis of bioenergetic failure.

How long has SS-31 been studied in clinical trials?

Clinical trial work on SS-31 spans over a decade, with more than 50 clinical trials completed or underway across indications including heart failure, kidney disease, Barth syndrome, and primary mitochondrial myopathy. The TAZPOWER Barth syndrome trial includes open-label extension data covering more than eight years of patient follow-up, making it among the longer longitudinal data sets available for any research peptide.

Is SS-31 the same as elamipretide or Bendavia?

Yes, all three names refer to the same compound. SS-31 is its research designation within the Szeto-Schiller peptide class naming system. Elamipretide is the international nonproprietary name used in clinical development. Bendavia was a brand name used during earlier clinical trial phases. Forzinity is the currently approved commercial brand name for the FDA-approved Barth syndrome indication. MTP-131 is an additional research designation used in some publications.

References

1. Chavez, J.D., et al. (2020). Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences, 117(26), 15363-15373. PubMed

2. Birk, A.V., et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250-1261. PubMed

3. Stuppard, R.S., et al. (2023). SS-31 and NMN treatments improve metabolic and functional dysfunctions in aged skeletal muscle. GeroScience, 45(4), 2031-2047. PubMed

4. Szeto, H.H. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 171(8), 2029-2050. PubMed

5. Campbell, M.D., et al. (2019). Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radical Biology and Medicine, 134, 268-280. PubMed

6. Hou, Y., et al. (2020). Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy. American Journal of Translational Research, 12(1), 1-14. PubMed

7. Liu, S., et al. (2022). SS-31 ameliorates ischemia/reperfusion-induced injury by restoring mitochondrial dynamics and autophagic flux in skeletal muscle. Journal of Cellular and Molecular Medicine, 26(7), 2048-2060. PubMed

8. Grosser, J.A., et al. (2021). Elamipretide reduces apoptosis in human neuroblastoma cells exposed to amyloid-beta. BMC Research Notes, 14(1), 64. PubMed

9. Zhao, W., et al. (2024). SS-31 peptide: A review of its mitochondria-targeting mechanisms and therapeutic applications. Mitochondrion, 76, 101846. PubMed

10. Reid Thompson, W., et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine, 23(3), 471-478. PubMed

11. Sabbah, H.N., et al. (2016). Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circulation: Heart Failure, 9(2), e002206. PubMed

12. Chatfield, K.C., et al. (2019). Elamipretide improves mitochondrial function in the failing human heart. JACC: Basic to Translational Science, 4(2), 147-157. PubMed

13. Butler, J., et al. (2020). Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF Phase 2 Trial. JACC: Heart Failure, 8(10), 798-811. PubMed

14. Saad, A., et al. (2017). Elamipretide (MTP-131) alters mitochondrial metabolism and attenuates oxidative damage in renal tubular cells from patients with renovascular disease. Journal of the American Heart Association, 6(8), e005892. PubMed

15. Karaa, A., et al. (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology, 90(14), e1212-e1221. PubMed

16. Karaa, A., et al. (2020). A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. Journal of Cachexia, Sarcopenia and Muscle, 11(4), 909-918. PubMed

17. Chiao, Y.A., et al. (2020). Late-life restoration of mitochondrial function reverses cardiac loss of the longevity-associated protein, SIRT3. eLife, 9, e55513. PubMed

18. Mitchell, W., et al. (2020). SS-31 (elamipretide) modulates the surface electrostatics of cardiolipin-containing lipid bilayers. Journal of Biological Chemistry, 295(40), 13764-13777. PubMed

19. Szeto, H.H., & Birk, A.V. (2014). Serendipitous discovery of Szeto-Schiller peptides: Mitochondria-targeted peptides for metabolic diseases and aging. Pharmaceutical Research, 31(10), 2669-2679. PubMed

20. Birk, A.V., et al. (2014). Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. British Journal of Pharmacology, 171(8), 2017-2028. PubMed